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Abstract 
Skeletal muscle (SKM) atrophy is a potentially debilitating condition induced by muscle 
disuse, denervation, many disease states, and aging. The ubiquitin proteasome pathway (UPP) 
contributes greatly to the protein loss suffered in muscle atrophy. The MERG1a K
+
 channel is 
known to induce UPP activity and atrophy in SKM. It has been further demonstrated that the 
mouse ether-a-gogo-related gene (Merg)1a channel modulates expression of MURF1, an E3 
ligase component of the UPP, while it does not affect expression of the UPP E3 ligase 
Mafbx/ATROGIN1. Because the UBR2 E3 ligase is known to participate in SKM atrophy, we 
have investigated the effect of Merg1a expression and hind limb suspension on Ubr2 
expression. Here, we report that hind limb suspension results in a significant 25.6% decrease in 
mouse gastrocnemius muscle fiber cross sectional area (CSA) and that electro-transfer of 
Merg1a alone into gastrocnemius muscles yields a 15.3% decrease in CSA after 7 days. More 
interestingly, we discovered that hind limb suspension caused a significant 8-fold increase in 
Merg1a expression and a significant 4.7-fold increase in Ubr2 transcript after 4 days, while 
electro-transfer of Merg1a into gastrocnemius muscles resulted in a significant 6.2-fold 
increase in Merg1a transcript after 4 days but had no effect on Ubr2 expression. In summary, 
the MERG1a K
+
 channel, known to induce atrophy and MURF1 E3 ligase expression, does not 
affect UBR2 E3 ligase transcript levels. Therefore, to date, the MERG1a channel’s 
contribution to UPP activity appears mainly to be through up-regulation of Murf1 gene 
expression. 
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 Skeletal muscle (SKM) can comprise 30-50% of body 
weight in humans and it functions in body movement, 
maintenance of posture and balance, soft tissue support, 
bolster of body entry and exit points and in temperature 
regulation. The loss of SKM mass and strength is 
referred to as atrophy and is known to result from 
unweighting, injury, denervation, disuse, disease (e.g., 
diabetes, cancer, etc.) and aging.
1-5
 Atrophy occurs 
when there is an imbalance in the processes of protein 
synthesis and protein degradation that favors protein 
loss. Numerous cellular pathways can contribute to 
SKM atrophy, including calpains, cathepsins and the 
ubiquitin proteasome pathway (UPP).
2,4
 The UPP is 
reported to be responsible for as much as 75% of the 
protein degradation that occurs during SKM atrophy
2,4,6
 
It is composed of three basic enzymes: E1 proteins 
which activate ubiquitin; E2 ubiquitin-conjugating 
molecules which accept the activated ubiquitin and 
interact with specific E3 enzymes; and the E3 ligase 
which binds target protein molecules and catalyzes the 
transfer of the ubiquitin from E2 to the E3-bound 
protein.
7,8
 A minimum of four ubiquitin molecules are 
required to be ligated to the target protein before it is 
degraded by the 26S proteasome. To date, only a few 
members of the E1 family have been identified (only 
two E1 enzymes have been detected within the human 
proteome) and over 50 E2 enzymes have been reported; 
however, several hundred potential E3 ligases have 
been described within mammalian genomes. Two main 
types of E3 enzymes have been described: the 
“homologous with E6-associated protein C6 terminus” 
(HECT) domain enzymes and the larger family of 
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“really interesting new gene” (RING) finger scaffold 
proteins. A newer described group of proteins with 
ubiquitin ligase activity, having atypical RING finger 
moieties,
9
 have been described and are often referred to 
as E4 enzymes. These have been reported to work in 
concert with E3 proteins to enhance their activity.
10
 
A number of E3 ligases have been identified as 
contributors to atrophy in SKM. Muscle ring finger-1 
(MURF1) and Muscle Atrophy F-box 
(Mafbx)/ATROGIN1 are RING finger E3 ligases 
specific to striated muscle that have been detected in 
several models of SKM atrophy, including 
unweighting, and are considered markers of 
atrophy.
1,2,4
 Ubiquitin ring-type (UBR, also referred to 
as E3) proteins are RING finger E3 ligases that are 
also reported to function in atrophic SKM, specifically 
cachexia-induced atrophy.
11
 The UBR box family of 
RING finger E3 ubiquitin ligases is composed of 
enzymes which recognize substrate proteins that have 
an N-degron; that is, the protein to be degraded has: 1) 
a destabilizing N-terminal residue; and 2) an internal 
lysine residue for ubiquitination.
7,12,13
 These enzymes 
are often referred to as N-recognins and this pattern of 
protein degradation, referred to as the N-end rule 
pathway, relates the identity of the N-terminal amino 
acid of a protein to its half-life in vivo
7,13,14
 UBR1 (also 
E3-I) was the first E3 ligase implicated in SKM 
atrophy
14,15
 and is believed to bind proteins that 
commence with unblocked hydrophobic or basic 
amino acids.
7, 16-19
 The UBR2 (also E3-II) member of 
the UBR family was described by Varshavsky and co-
workers.
17
 In 2004, Kwak et al. demonstrated that both 
the Ubr1 and 2 homologues are up-regulated in the 
atrophying SKM of rats bearing malignant tumors.
11
 
However, it was concluded that the UBR2 isoform is 
more critically involved in the process because it is 
more specifically expressed in SKM tissue and is 
detected at the early onset of atrophy while UBR1 is 
not. In fact, a recent study suggests that tumor cell-
induced up-regulation of Ubr2 expression in skeletal 
muscle may be mediated by the p38-C/EBP 
signaling pathway. 
19
 
The ether-a-gogo- related gene (ERG)1a K
+
 channel is 
known to be partially responsible for late phase 
repolarization of the cardiac action potential in many 
mammalian species, including mice and humans.
21
 Our 
laboratory has demonstrated that this channel is up-
regulated in the SKM of mice experiencing atrophy as 
a result of both hind limb suspension (unweighting) 
and cancer cachexia.
22
 Further, we have demonstrated 
that electro-transfer of Merg1a alone into the SKM of 
weight bearing mice induces atrophy and, importantly, 
that electro-transfer of Merg1a into mouse SKM up-
regulates UPP activity. More recently, we have shown 
that electro-transfer of Merg1a into mouse SKM up-
regulates the expression of the E3 ligase Murf1, but not 
Mafbx/ATROGIN1.
22
 Because of its link to atrophy 
with both unweighting and cachexia, we asked if 
Merg1a expression would also modulate expression of 
the Ubr2 E3 ligase gene. Here, we have determined the 
time course of Merg1a and Ubr2 expression in 
response to both hind limb suspension and electro-
transfer of the Merg1a K+ channel and show that, 
although Ubr2 is expressed in response to hindlimb 
suspension, its expression is not modulated by Merg1a 
expressed alone. 
Materials and Methods 
Animals. The Purdue Animal Care and Use Committee 
approved all procedures. ND4-Swiss Webster male 
mice at 8 weeks age (Harlan-Sprague; Indianapolis, 
IN) were used in all procedures. Animals were 
provided food and water ad libitum, housed in Purdue 
University animal facilities on a 12 hour light/dark 
cycle and monitored by lab animal veterinarians. At 
completion of all studies, anesthetized animals were 
humanely killed according to the approved protocol 
prior to harvest of the gastrocnemius muscles (GMs). 
Hind Limb Suspension. Custom suspension cages were 
assembled as described earlier.
23
 Animals were 
positioned in these cages resting in an approximate 30 
head down tilt with their hind limbs raised off of the 
floor so that they were unable to place any weight on 
them. Commercial mouse cages were used to house 
control mice in a natural weight bearing state.  
Tissue Sectioning, Staining and CSA Determination. 
GMs were embedded using OCT™ (Electron 
Microscopy Sciences; Hatfield, PA), cryo-sectioned 
(12 m) and stained for β–galactosidase (LACZ) 
activity as described previously.
21
 Images of sections 
were captured with a Leaf Micro–Lumina digital 
camera (Scitex; Tel-Aviv, Israel). The CSA (m2) of 
each muscle fiber was determined using a micrometer 
slide and Image J software (NIH; Bethesda, MD).  
Plasmids. The Merg1a clone in pBK/CMV
24
 was a 
generous gift from Dr. Barry London (Cardiovascular 
Institute, University of Pittsburgh, PA). The CMV-
lacZ in pNL vector was purchased from the Center 
Commercial de Gros (Toulouse, France). 
Electro-transfer. Mice were anesthetized using 10 l/g 
body weight of xylazine (1 mg/ml) and ketamine (9 
mg/ml) in sterile saline according to an approved 
protocol. Hind limbs were shaved and the both GMs 
were injected with expression plasmid (see Study 2 
below) in 50 l sterile saline. Eight electrical pulses at 
200V/cm for 20 ms at 1 Hertz were applied to all lower 
limbs (GMs) with an ECM 830 ElectroSquare Porator 
(BTX; Hawthorne, NY). This method results in gene 
transcription and translation in SKM in our 
laboratory.
22,23,25
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Real Time PCR. Trizol reagent (Invitrogen; Carlsbad, 
CA) was used to extract total RNA from GMs 
according to manufacturer’s instructions. 
Phenol/chloroform extraction and ethanol precipitation 
sequentially followed the extraction. Contaminating 
DNA was degraded by two 10 min treatments with 
DNase I (ProMega; Madison, WI) and the DNase was 
subsequently heat inactivated. A GoScript™ Reverse 
Transcriptase Kit (ProMega; Madison, WI) was used to 
reverse transcribe cDNA using an Eppendorf 
Mastercycler Personal (Hauppauge, NY). PerfeCTa 
SYBR Green Supermix for iQ (Quanta Biosciences, 
Inc.; Gaithersberg, MD) was added to the PCR reaction 
(per manufacturer’s instructions) and primers (see 
Table 1) for the gene of interest were added to the 
samples (in triplicate) while primers for an appropriate 
“housekeeping” gene (the 18S ribosomal subunit) were 
added to identical samples (in triplicate). A BioRad 
MyiQ single Color Real time PCR Detection System 
(BioRad; Hercules, CA) was used to detect SYBR 
Green fluorescence as a measure of amplicon. Sample 
CT values were normalized to (subtracted from) the 
CT values of the 18S “housekeeping” gene and the 
number 2 was raised to a power equal to the difference 
between the sample CT values of the 18S subunit and 
the gene of interest.
22,23,25
 
Study 1 Experimental Design. Three groups of five 
mice each were hindlimb suspended
22
 for either 2, 4 or 
7 days. A fourth group of five mice were allowed to 
remain weight bearing and were used as day 0 controls 
(n=20). After the assigned control or suspension 
duration, each group of mice was killed according to 
the approved protocol and the GMs were harvested and 
flash frozen in liquid nitrogen. The left GMs from all 
mice were prepared for real time PCR and thus assayed 
for expression of Merg1a and Ubr2 genes (see above). 
Normalized sample CT values for the Day 0 control 
were averaged and the fold increase in gene expression 
for each gene per mouse was determined by calculating 
the ratio of each daily mouse sample gene expression 
value to the average Day 0 value.  
Study 2 Experimental Design. All GMs of 20 mice (4 
groups of 5 each) were injected with 10 g LacZ and 
20 g Merg1a expression plasmid and were subjected 
to electro-transfer as described above. A group of 5 
mice each was killed at days 0, 2, 4 and 7 after electro-
transfer
22,23,25
 and the GMs from all legs were 
harvested and flash frozen in liquid nitrogen. The GMs 
from the left legs were cryo-sectioned and stained for 
LACZ activity as a marker for gene expression while 
right legs were prepared for real time PCR as described 
above. Because a greater abundance (2X) of Merg1a 
than LacZ expression plasmid was injected, we assume 
that all myofibers staining for LACZ reporter activity 
also express Merg1a and that those myofibers not 
staining for LACZ activity are not expressing plasmid.  
Statistics. Data were analyzed by ANOVA using a 
completely randomized design. When significant 
differences were found, means were separated by 
Fisher's Protected Least Significant Difference. All 
data were analyzed using the General Linear Model 
Procedure of SAS (SAS Institute Inc.; Cary, NC). All 
statements of significance are p≤0.05. 
 
Figure 1. Hind limb suspension causes SKM 
atrophy and up-regulation of both 
Merg1a and Ubr2 E3 ligase expression. 
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Results and Discussion 
Study 1. Hind limb suspension causes SKM atrophy 
and up-regulation of both Merg1a and Ubr2 E3 ligase 
expression.  
Similar to earlier studies conducted in our laboratory,
22
 
hindlimb suspension caused decreases in myofiber 
CSA at Day 2 (2%) and Day 4 (8.7%), but the 
decreases are not statistically significant (Figure 1B). 
The 25.6% decrease at Day 7, however, is statistically 
significant. Also, similar to other studies we have 
conducted,
23
 hind limb suspension does not result in a 
statistically significant increase in Merg1a K
+
 channel 
expression at Day 2; however, it does result in a 
significant 8-fold increase in the expression of the 
Merg1a K
+
 channel by Day 4 (Figure 1A). The level of 
Merg1a K
+
 channel transcript decreases from that of 
Day 4 by Day7 although it remains significantly higher 
(4.1 fold) than Day 0. 
Study 2. Ectopic expression of the Merg1a K+ channel 
gene induces atrophy, but not expression of the gene 
encoding the Ubr2 E3 ligase. Reminiscent of earlier 
work in our laboratory,
22
 myofiber CSA drops by 3.1% 
(Figure 2B) after 4 days of Merg1a ectopic expression. 
Myofiber CSA drops by a statistically significant 
15.3% after seven days of Merg1a expression, 
demonstrating that Merg1a expression induces SKM 
atrophy. In response to injection of Merg1a expression 
plasmid into GM followed by electro-transfer, Merg1a 
transcript is produced as shown earlier.
22,23,25
 Levels of 
this transcript increase 1.7-fold by Day 2 and then to a 
statistically significant higher 6.2 fold level by Day 4. 
The Merg1a transcript level drops by day 7, but is still 
a significant 3.8 fold higher than it was at Day 0 
(Figure 2A). In contrast, Ubr2 gene expression does 
not increase in response to ectopic Merg1a gene 
expression. SKM atrophy occurs as a result of an 
imbalance in protein synthesis and protein degradation 
which ultimately favors protein loss and muscle 
deterioration. The UPP, comprised of E1, E2 and E3 
enzymes, is reported to be responsible for a large 
portion of the protein degradation that occurs in 
atrophying muscle.
1-6
 The E3 ligases MURF1 and 
Mafbx/ATROGIN1 are ring finger E3 ligases specific 
to striated muscle which contribute greatly to skeletal 
muscle atrophy induced by numerous factors.
1-4
 
Our laboratory reported that the Merg1a K
+
 channel is 
expressed at high levels in the GMs of mice 
experiencing atrophy as a result of both hind limb 
suspension and cancer cachexia while it is basically 
undetected in the matched muscles of appropriate 
control animals.
22 
We have also shown that the atrophy 
resulting from hind limb suspension can be inhibited 
by ectopic expression (resulting from electro-transfer) 
of the dysfunctional Merg1a mutant, DN-Merg1a, in 
the GMs as well as by treatment with astemizole, a 
known pharmacological ERG1 channel blocker. 
Further, electro-transfer of the Merg1a K
+
 channel 
gene into mouse GM induces atrophy and, importantly, 
increases UPP activity.
22
 The mechanism(s) by which 
MERG1a modulates UPP activity is not known; 
however, we recently demonstrated that Merg1a 
expression does not modulate expression of 
 
 
Figure 2. Ectopic expression of the Merg1a K+ 
channel gene induces atrophy, but not 
expression of the gene encoding the 
Ubr2 E3 ligase. 
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Mafbx/ATROGIN1, although it does indeed increase 
the levels of both MURF1 transcript and protein.
23
 
This separation of MURF1 and Mafbx/ATROGIN1 
modulation at the level of a membrane protein is most 
interesting. Because the literature reports that Murf1 
transcription, and not that of Mafbx, is increased by 
NF-B factors26 and that NF-B is basically required 
for disuse muscle atrophy
26-28
 this separation of E3 
ligase modulation suggests that MERG1a may be 
modulating Murf1 expression through NF-B activity. 
Indeed, a study by Wang et al. (2002), reveals that 
cells expressing HERG have higher endogenous levels 
of the active form of NF-B than those cell lines with 
little to non-detectable levels of endogenous HERG.
29
 
Certainly these findings beg for further exploration 
into the potential effect of MERG1a on the NF-B 
family of transcription factors (likely through the IKK-
/IB-/NF-B pathway) as well as the potential 
modulation of FOXO1 and 4 transcription factors 
(potentially through the PI3K/AKT/FOXO pathway). 
1,4,26,30
 Obviously, the MERG1a K
+
 channel may also 
interact with other known or unknown pathways. 
Our data show that hind limb suspension decreases 
mouse GM CSA by 25.6% while ectopic Merg1a 
expression alone induces an approximately 10% lower 
(15.3%) decline in GM CSA. This demonstrates that 
Merg1a expression and the consequences of this 
channel up-regulation are not solely responsible for 
SKM atrophy. Indeed, we have already shown that 
Merg1a expression does not induce expression of 
Mafbx/Atrogin1,
23
 an E3 ligase known to be 
responsible for a large percentage of SKM atrophy 
induced by immobilization,
30
 although it does induce 
expression of MuRF1,
23
 another E3 ligase important to 
immobilization induced SKM atrophy.
30
 To further 
explore the potential effects of Merg1a expression on 
SKM and its contributions to the atrophic process, we 
decided to determine if a member of the UBR family 
of ligases, known to be involved in SKM atrophy, is 
modulated by MERG1a. The UBR1 and UBR2 E3 
ligases are two members of the UBR family (recently 
described as having 7 constituents) which are known to 
recognize substrate proteins having a destabilizing N-
terminal residue and an internal lysine residue for 
ubiquitin conjugation.
31
 Expression of these E3 ligases 
is induced in skeletal muscle undergoing atrophy as a 
result of cancer cachexia, although Ubr2 is up-
regulated earlier in the atrophic time course and also 
more dramatically and more specifically than Ubr1.
20
 
In fact, Ubr2 up-regulation in the GMs of mice bearing 
malignant tumors is reported to occur within the time 
frame during which Merg1a expression is highest in 
both suspended mice and in those expressing Merg1a 
as a result of electro-transfer (during the first 7 days). 
The reported Ubr1 expression time frame for cachectic 
mice (second week) does not correlate well with the 
Merg1a expression time courses we have reported for 
either hind limb suspended or mice ectopically 
expressing Merg1a.
23
 The existing data suggest that 
Merg1a levels would be low when Ubr1 levels are 
demonstrated to begin to increase, so that the increase 
in Ubr1 transcript levels would not likely be a direct 
result of Merg1a expression. 
Although, it is possible that the time course for 
Merg1a expression is more drawn out in mice 
experiencing muscle atrophy as a result of cancer 
cachexia, we nonetheless designed Ubr2 specific 
primers and monitored the time course of Ubr2 
expression in response to both hind limb suspension 
and electro-transfer of Merg1a into the GMs of mice. 
We discovered that, although hind limb suspension 
does induce transcription of both Merg1a and Ubr2 
within seven days of suspension, Merg1a expression 
alone is not sufficient to yield increased levels of Ubr2 
transcript within this time frame. One might speculate 
that the electro-transfer of Merg1a into GMs needs 
additional time for insertion of this K
+
 channel into the 
plasma membrane and physiological activation. 
However, our earlier work,
22,23
 demonstrated that the 
time frame applied (7 days post electro-transfer of 
Merg1a) does indeed produce both transcription 
(rtPCR) and translation (western blotting) of the 
Merg1a construct and a statistically significant 16% 
(p<0.05) decrease in GM CSA. We also have shown 
that this decrease in CSA can be inhibited by co-
electro-transfer and co-expression of Merg1a and a 
dominant negative (i.e., dysfunctional pore mutant) 
form of the Merg1a channel 7 days after electro-
transfer into skm.
22
 The inhibition of Merg1a-induced 
atrophy by this dysfunctional pore mutant 
demonstrates that the electro-transferred Merg1a K
+
 
channel is functional. Further, we have shown that 
both pharmacological treatment of mice with an ERG 
channel pore blocker (oral gavage with astemizole) and 
electro-transfer of the dominant negative Merg1a into 
GM of hind limb suspended mice inhibited atrophy 
(i.e., inhibited the decrease in muscle fiber CSA,
22
). 
This evidence demonstrates (albeit indirectly) that the 
MERG1a channel is functional (located in the 
membrane and conducting current) within 7 days of 
electro-transfer. Therefore, it appears that Merg1a 
expression alone does not affect expression of Ubr2 
within 7 days; nonetheless, it is still feasible that an 
even longer post electro-transfer time frame may be 
necessary for adequate activation of the MERG1a 
channel to induce Ubr2 transcription. Further, this 
work does not rule out the possibility that MERG1a 
may affect or interact with some other factor produced 
during hind limb suspension which induces or 
participates in the induction of Ubr2 expression. For 
example, HERG protein and current expression is 
known to be regulated by kinases such as stress-
responsive serum- and glucocorticoid-inducible kinase 
isoforms SGK1 and 3 in HEK cells,
32
 protein kinase 
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A
33
 and AMP-dependent protein kinase (AMPK; 1). It 
is possible that such a factor(s) is necessary to 
modulate channel activity and produce atrophy and, 
although present during hindlimb suspension, is not 
present when Merg1a is electro-transferred into 
muscle. We also must consider that the electro-transfer 
itself could interfere with the presence or production of 
some factor necessary for MERG1a-induced Ubr2 
transcription, although we have not produced or read 
any evidence of this. Of course, even though we have 
shown that our system of Merg1a electro-transfer into 
mouse GMs will induce transcription of significant 
levels of Merg1a and the MuRF1 E3 ligase,
22,23
 the 
simplest issue may be that it may not have produced 
the levels of MERG1a necessary to induce Ubr2 
transcription.
 
Finally, our work does not rule out the possibility that 
MERG1a may affect Ubr2 expression in muscle 
atrophying as a result of cancer cachexia. Previous 
studies support the existence of potential cellular 
connections between UBR2 and ERG. For example, 
Ubr2 expression is reported to activate the pro-
inflammatory cytokine tumor necrosis factor-alpha 
(TNF-), which is involved in the onset of 
cachexia;
11,29
 and, interestingly, TNF- stimulation of 
TNF receptor 1 (TNFR1) has been shown to impair 
human ERG (HERG)/IKr current density (and prolong 
action potential duration) by stimulation of reactive 
oxygen species in canine cardiomyocytes.
33
 Is it 
possible that TNF- binds its receptor and affects ERG 
in such a way as to affect Ubr2 expression? Work by 
Wang et al., (2002) demonstrates that TNF- affects 
cell growth and apoptosis more stringently in cells 
expressing ERG than those that do not, suggesting that 
TNFR1 may be more abundant in the ERG-expressing 
cells.
34
Further, it is reported that cells positive for 
endogenous ERG protein also contained more 
abundant TNFR1 than cells that did not express high 
levels of endogenous ERG, suggesting that perhaps 
ERG channels somehow recruit TNFR1 to the cell 
membrane. Indeed, the same study showed that HERG 
and TNFR1 co-immunoprecipitate from cell lysates.
34
 
Therefore, it does seem reasonable to suggest that, 
although Merg1a expression alone may not induce 
Ubr2 expression, it may do so as a result of some 
missing factor that may be more significantly abundant 
under physiological atrophy producing conditions.  
To our knowledge, this is the first report of an increase 
in Ubr2 expression in SKM as a response to disuse 
atrophy and also the first exploration of possible 
modulation of Ubr2 E3 ligase expression by MERG1a. 
We conclude that, although hind limb suspension of 
mice induces an increased expression of genes 
encoding Merg1a and Ubr2 in GMs, the electro-
transfer (and subsequent expression) of Merg1a alone 
into GMs of mice does not affect expression of Ubr2 
within 7 days of electro-transfer. The data suggest that 
either Merg1a does not affect Ubr2 expression or that, 
if it does, then it either needs more than 7 days to 
induce this expression or it must have access to another 
factor, one induced by conditions produced during 
skeletal muscle atrophy resulting from disuse and/or 
cancer cachexia. 
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